scholarly journals Anti-atherosclerotic effects between a combined treatment with simvastatin plus hirudin and single simvastatin therapy in patients with early type 2 diabetes mellitus

2019 ◽  
Vol 7 (14) ◽  
pp. 302-302
Author(s):  
De-Qiang Li ◽  
Fei-Fei Lv ◽  
Zhong-Chun Li ◽  
Zhi-Yuan Dai ◽  
Hong-Xia Wang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Treatment ◽  
Early Type ◽  
Simvastatin Therapy

scholarly journals Prevalence of Anaemia and Its Associated Factors among Type 2 Diabetes Mellitus Patients in University of Gondar Comprehensive Specialized Hospital

Anemia ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Sewnet Adem Kebede ◽  
Biruk Shalmeno Tusa ◽  
Adisu Birhanu Weldesenbet
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Associated Factors ◽  
Microvascular Complications ◽  
Combined Treatment ◽  
Factors Associated ◽  
Specialized Hospital ◽  
Patients With Diabetes

Background. Anaemia is one of the commonest blood disorders seen in patients with diabetes. In Ethiopia, chronic illnesses are tremendously raising with their complications. But very little research has been conducted, particularly on anaemia among diabetes mellitus (DM) patients. Therefore, this study aimed at assessing the prevalence of anaemia and associated factors among type 2 diabetes mellitus patients in Northwest Ethiopia. Methods. A cross-sectional study design was employed at University of Gondar Comprehensive Specialized Hospital from March 1 to April 15, 2019, among 372 type 2 diabetes mellitus patients (T2DM). Multivariable logistic regression analysis was fitted, and the corresponding adjusted odds ratio (AOR) and 95% CI were used to identify factors associated with anaemia. Level of significance was declared at the p value less than 0.05. Results. The study revealed 8.06% (95% CI: 5.68–11.31%) of the participants were anaemic. Being male (AOR = 2.74, CI: 1.02, 7.38), combined type of treatment (AOR = 8.38, CI: 1.66, 42.25), having diabetes-related microvascular complications (AOR = 3.24, CI: 1.14, 9.26), and hypertension (AOR = 0.01, CI: 0.002, 0.06) were the significant factors associated with anaemia. Conclusions. The finding of the current study revealed low prevalence of anaemia among T2DM patients. Sex, type of treatment, diabetes-related microvascular complications, and hypertension were factors associated with anaemia. Assessment of haemoglobin levels among T2DM patients may help to prevent ensuing microvascular complications. Incorporate anaemia screening into the routine assessment of diabetic complication particularly for those who are hypertensive and took combined treatment to allow early appreciation and treatment of anaemia and later improve the overall care of patients with diabetes.

scholarly journals Visual changes in patients with early type 2 diabetes mellitus without diabetic retinopathy due to possible subclinical ischemia

2019 ◽  
Vol 97 (S263) ◽  
Author(s):  
María José Vicente ◽  
Elisa Vilades ◽  
Elvira Orduna ◽  
Beatriz Cordón ◽  
Javier Pérez‐Velilla ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Early Type ◽  
Visual Changes

Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus

2006 ◽  
Vol 188 (2) ◽  
pp. 455-461 ◽  
Author(s):  
Vincenzo Solfrizzi ◽  
Cristiano Capurso ◽  
Anna M. Colacicco ◽  
Alessia D’Introno ◽  
Cristina Fontana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Treatment ◽  
Serum Levels ◽  
Lipoprotein A

scholarly journals Efficacy of combined treatment of distal polyneuropathy in patients with type 2 diabetes mellitus and concomitant primaryhypothyroidism

2011 ◽  
Vol 14 (3) ◽  
pp. 76-79
Author(s):  
Inessa Ivanovna Dubinina ◽  
Tatiana Vladimirovna Karapysh ◽  
Nina Fedorovna Nosova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Metabolic Parameters ◽  
Postprandial Glycemia ◽  
Thyroid Pathology ◽  
Hba1c Levels

Aim. To study changes of metabolic parameters and neurologic manifestations in patients with type 2 diabetes mellitus and concomitant primaryhypothyroidism under effect of combined therapy. Materials and methods. 62 patients with distal neuropathy (DN) including 16 with DM2 and primary hypothyroidism (PHT) (group 1), 32 DM2patients without thyroid pathology (group 2), and 15 patients with PHT without DM (group 3). The patients were matched for age and durationof all above diseases. They were treated by alpha lipoic acid-based drugs: thioctacid, thiogamma, berlithion, octolipen (600 U/d i/v), vitamins B:milgamma, combilipen (2 ml/d i/m) for 12 weeks. All measurements were made at admittance, 21 days and 12 weeks after it. The efficacy of therapywas estimated from changes in HbA1c levels, fasting and postprandial glycemia, lipid metabolism. DN was diagnosed using NSS, TSS, NDS, NDSm,and NIS-LL scales. Results. Combined therapy of patients with DM2 and PHT resulted in a decrease of HbA1c levels within 12 weeks, fasting and postprandialglycemia within 21 and 12 weeks respectively. Compensation of PHT led to a decrease of total cholesterol and triglyceride levels within 12 weeks.Subcompensation of carbohydrate metabolism (postprandial glycemia) improved neurologic symptoms within 21 weeks in all patients (NSS and TSSscales). The same effect was documented within 12 weeks in patients without thyroid pathology (NSS, TSS, NDS, NDSm, and NIS-LL scales). Inthose with PHT beneficial effect was revealed only using the NIS-LL scale. The worst outcome of therapy estimated from NSS, TSS, NDS, NDSm,and NIS-LL scales was documented in patients with DM2+PHT probably due to additional effect of thyroid pathology on the severity of DN. Conclusion. The use of NSS, TSS, NDS, NDSm, and NIS-LL scales makes it possible to reveal changes in the severity of sensorimotor disturbancesin DN patients depending on metabolic parameters modified by pathogenetic therapy.

Sign in / Sign up

Export Citation Format

Share Document